Neurocrine Pays $165M to Bankroll Voyager?s Gene Therapy for Parkinson?s

The road to potential approval for Voyager Therapeutics? experimental gene therapy for Parkinson?s disease got a bit longer, and more expensive, last year. So this morning the company cut a deal with Neurocrine Biosciences to bankroll the journey?and forfeit some of the financial upside for the product, known as VY-AADC. Neurocrine (NASDAQ: NBIX) has agreed [?]